First Washington CORP held its position in shares of Intrexon Corporation (NYSE:XON) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 154,530 shares of the biotechnology company’s stock at the close of the second quarter. Intrexon Corporation accounts for approximately 1.9% of First Washington CORP’s investment portfolio, making the stock its 24th largest position. First Washington CORP owned about 0.13% of Intrexon Corporation worth $3,723,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Intrexon Corporation by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after purchasing an additional 226,090 shares in the last quarter. Iridian Asset Management LLC CT boosted its position in shares of Intrexon Corporation by 2.4% during the 1st quarter. Iridian Asset Management LLC CT now owns 3,853,274 shares of the biotechnology company’s stock valued at $76,372,000 after purchasing an additional 91,565 shares in the last quarter. State Street Corp boosted its position in shares of Intrexon Corporation by 34.0% during the 1st quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock valued at $53,664,000 after purchasing an additional 687,406 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Intrexon Corporation by 32.5% during the 2nd quarter. First Trust Advisors LP now owns 1,537,088 shares of the biotechnology company’s stock valued at $37,028,000 after purchasing an additional 376,780 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Intrexon Corporation by 3.5% during the 1st quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock valued at $8,513,000 after purchasing an additional 14,674 shares in the last quarter. Institutional investors own 82.27% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Northland Securities set a $30.00 price objective on shares of Intrexon Corporation and gave the company a “buy” rating in a research report on Monday, August 7th. BidaskClub lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Intrexon Corporation currently has a consensus rating of “Hold” and an average target price of $37.60.
Shares of Intrexon Corporation (NYSE:XON) traded down 0.81% on Tuesday, hitting $19.69. 176,305 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $19.96 and its 200 day moving average price is $21.50. The company’s market cap is $2.37 billion. Intrexon Corporation has a 1-year low of $17.03 and a 1-year high of $32.90.
Intrexon Corporation (NYSE:XON) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.42) EPS. On average, equities research analysts expect that Intrexon Corporation will post ($0.87) earnings per share for the current year.
In related news, Director Dean J. Mitchell bought 5,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The stock was bought at an average cost of $18.33 per share, for a total transaction of $91,650.00. Following the transaction, the director now owns 18,103 shares of the company’s stock, valued at $331,827.99. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Andrew J. Last bought 2,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were bought at an average price of $19.99 per share, with a total value of $39,980.00. Following the completion of the transaction, the chief operating officer now directly owns 2,000 shares in the company, valued at approximately $39,980. The disclosure for this purchase can be found here. Insiders have bought a total of 144,569 shares of company stock valued at $2,719,429 over the last 90 days. Corporate insiders own 56.30% of the company’s stock.
Intrexon Corporation Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.